• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

含跨膜段的表皮生长因子受体胞外结构域在表皮生长因子处理下的二聚化。

Dimerization of the extracellular domain of the receptor for epidermal growth factor containing the membrane-spanning segment in response to treatment with epidermal growth factor.

作者信息

Tanner K G, Kyte J

机构信息

Department of Chemistry 0506, University of California at San Diego, La Jolla, California 92093-0506, USA.

出版信息

J Biol Chem. 1999 Dec 10;274(50):35985-90. doi: 10.1074/jbc.274.50.35985.

DOI:10.1074/jbc.274.50.35985
PMID:10585488
Abstract

A recombinant fragment of the human receptor for epidermal growth factor containing both its extracellular domain and its membrane-spanning segment, when dissolved with Triton X-100, was observed to dimerize in response to addition of epidermal growth factor (EGF) even at the lowest concentration of this fragment that could be assayed (4 nM). Consequently, the dissociation constant for the dimer of this fragment is at least 10,000-fold smaller than that for dimers of soluble, recombinant forms of the extracellular domain lacking the membrane-spanning segment. The second-order rate constant for dimerization of the fragment containing the extracellular domain and the membrane-spanning segment was estimated to be greater than 0.3 nM(-1) min(-1), more than 10-fold that of the native enzyme under the same conditions. This result suggests that the cytoplasmic domain of the intact enzyme sterically hinders its dimerization. When EGF is removed from the dimer of the fragment, the rate constant for its dissociation is greater than 0.2 min(-1), more than 40-fold that of the native enzyme. This result suggests that interfaces between cytoplasmic domains of intact EGF receptor impart significant stabilization to the dimer of the enzyme.

摘要

人表皮生长因子受体的一个重组片段,包含其胞外结构域和跨膜片段,当用Triton X - 100溶解时,即使在可检测的该片段最低浓度(4 nM)下,加入表皮生长因子(EGF)后也会发生二聚化。因此,该片段二聚体的解离常数比缺乏跨膜片段的可溶性重组胞外结构域二聚体的解离常数至少小10000倍。含有胞外结构域和跨膜片段的片段二聚化的二级速率常数估计大于0.3 nM⁻¹ min⁻¹,是相同条件下天然酶的10倍以上。这一结果表明完整酶的胞质结构域在空间上阻碍了其二聚化。当从片段二聚体中去除EGF时,其解离速率常数大于0.2 min⁻¹,是天然酶的40倍以上。这一结果表明完整EGF受体胞质结构域之间的界面赋予了该酶二聚体显著的稳定性。

相似文献

1
Dimerization of the extracellular domain of the receptor for epidermal growth factor containing the membrane-spanning segment in response to treatment with epidermal growth factor.含跨膜段的表皮生长因子受体胞外结构域在表皮生长因子处理下的二聚化。
J Biol Chem. 1999 Dec 10;274(50):35985-90. doi: 10.1074/jbc.274.50.35985.
2
The extracellular domain of the epidermal growth factor receptor. Studies on the affinity and stoichiometry of binding, receptor dimerization and a binding-domain mutant.表皮生长因子受体的细胞外结构域。结合亲和力与化学计量学、受体二聚化及结合结构域突变体的研究
Eur J Biochem. 1994 Oct 1;225(1):223-33. doi: 10.1111/j.1432-1033.1994.00223.x.
3
Ligand-binding enhances the affinity of dimerization of the extracellular domain of the epidermal growth factor receptor.配体结合增强了表皮生长因子受体细胞外结构域二聚化的亲和力。
J Biochem. 1997 Jul;122(1):116-21. doi: 10.1093/oxfordjournals.jbchem.a021718.
4
EGF induces increased ligand binding affinity and dimerization of soluble epidermal growth factor (EGF) receptor extracellular domain.表皮生长因子(EGF)可诱导可溶性表皮生长因子(EGF)受体胞外域的配体结合亲和力增加及二聚化。
J Biol Chem. 1991 Nov 15;266(32):22035-43.
5
Secondary dimerization between members of the epidermal growth factor receptor family.表皮生长因子受体家族成员之间的继发性二聚化。
J Biol Chem. 1997 May 2;272(18):12052-6. doi: 10.1074/jbc.272.18.12052.
6
Epidermal growth factor (EGF) induces oligomerization of soluble, extracellular, ligand-binding domain of EGF receptor. A low resolution projection structure of the ligand-binding domain.表皮生长因子(EGF)可诱导表皮生长因子受体可溶性细胞外配体结合结构域发生寡聚化。配体结合结构域的低分辨率投影结构。
J Biol Chem. 1991 Jul 25;266(21):13828-33.
7
A 40-kDa epidermal growth factor/transforming growth factor alpha-binding domain produced by limited proteolysis of the extracellular domain of the epidermal growth factor receptor.一种通过对表皮生长因子受体胞外域进行有限蛋白酶解产生的40千道尔顿表皮生长因子/转化生长因子α结合结构域。
J Biol Chem. 1993 Jan 25;268(3):1976-81.
8
Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment.近膜段激活表皮生长因子受体催化结构域的机制。
Cell. 2009 Jun 26;137(7):1293-307. doi: 10.1016/j.cell.2009.04.025.
9
EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization.表皮生长因子通过消除自身抑制胞外域二聚化的相互作用来激活其受体。
Mol Cell. 2003 Feb;11(2):507-17. doi: 10.1016/s1097-2765(03)00047-9.
10
Real-time measurements of kinetics of EGF binding to soluble EGF receptor monomers and dimers support the dimerization model for receptor activation.对表皮生长因子(EGF)与可溶性表皮生长因子受体单体和二聚体结合动力学的实时测量支持了受体激活的二聚化模型。
Biochemistry. 1993 Aug 17;32(32):8193-8. doi: 10.1021/bi00083a020.

引用本文的文献

1
Fourth-generation EGFR-TKI to overcome C797S mutation: past, present, and future.克服C797S突变的第四代表皮生长因子受体酪氨酸激酶抑制剂:过去、现在与未来
J Enzyme Inhib Med Chem. 2025 Dec;40(1):2481392. doi: 10.1080/14756366.2025.2481392. Epub 2025 Apr 2.
2
Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations.表皮生长因子受体酪氨酸激酶抑制剂纪事:靶向含三重突变的表皮生长因子受体C797S
Biomol Ther (Seoul). 2022 Jan 1;30(1):19-27. doi: 10.4062/biomolther.2021.047.
3
Transmembrane Peptides as Inhibitors of Protein-Protein Interactions: An Efficient Strategy to Target Cancer Cells?
跨膜肽作为蛋白质-蛋白质相互作用的抑制剂:一种靶向癌细胞的有效策略?
Front Oncol. 2020 Apr 15;10:519. doi: 10.3389/fonc.2020.00519. eCollection 2020.
4
The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers.HER3 通路作为抑制胆道癌患者的潜在靶点。
PLoS One. 2018 Oct 18;13(10):e0206007. doi: 10.1371/journal.pone.0206007. eCollection 2018.
5
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways.表皮生长因子受体细胞增殖信号通路
Cancers (Basel). 2017 May 17;9(5):52. doi: 10.3390/cancers9050052.
6
FGFR3 unliganded dimer stabilization by the juxtamembrane domain.通过近膜结构域实现成纤维细胞生长因子受体3(FGFR3)无配体二聚体的稳定化。
J Mol Biol. 2015 Apr 24;427(8):1705-14. doi: 10.1016/j.jmb.2015.02.013. Epub 2015 Feb 15.
7
Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab.在胆管癌中 EGFR、HER2 和 HER3 的过表达和基因扩增,以及使用 HER2 靶向抗体 pertuzumab 进行治疗的可能性。
J Gastroenterol. 2015 Apr;50(4):467-79. doi: 10.1007/s00535-014-0984-5. Epub 2014 Aug 12.
8
Cetuximab and biomarkers in non-small-cell lung carcinoma.西妥昔单抗与非小细胞肺癌中的生物标志物
Biologics. 2012;6:221-31. doi: 10.2147/BTT.S24217. Epub 2012 Jul 13.
9
Mutations in or near the transmembrane domain alter PMEL amyloid formation from functional to pathogenic.跨膜结构域中的突变或附近的突变将 PMEL 淀粉样蛋白从功能性转变为致病性。
PLoS Genet. 2011 Sep;7(9):e1002286. doi: 10.1371/journal.pgen.1002286. Epub 2011 Sep 15.
10
The SCHOOL of nature: I. Transmembrane signaling.自然之学派:I. 跨膜信号传导
Self Nonself. 2010 Jan;1(1):4-39. doi: 10.4161/self.1.1.10832.